In vivo molecular diagnostics in Alzheimer’s Disease (LeARN)

Download Profile PDF
At a Glance
  • Status: Completed Consortium
  • Year Launched: 2008
  • Initiating Organization: Center for Translational Molecular Medicine (CTMM)
  • Initiator Type: Government
  • Disease focus:
    Alzheimer's Disease
  • Location: Europe

Abstract

Mission

Age-related cognitive impairment and dementia impose an increasing burden on aging Western societies in terms of diminished quality-of-life and high healthcare costs (approximately €3 billion annually in the Netherlands). Memory loss is often regarded by patients as an indication that they may have Alzheimer’s Disease (AD), although in practice it is also a symptom of many far less serious conditions. An important challenge is therefore to differentiate those patients who will not develop dementia (who can thus be comforted) from those who will develop full-blown AD with dementia (for whom healthcare should be provided).

This project aims to develop new instruments with which to make an earlier and more reliable diagnosis of AD during life and create the conditions for an effective evaluation of novel medication therapies for AD patients.

These aims will be achieved by developing the following:

Consortium History

July 2008: Project began

Points of Contact

Principal Investigator
M. A. van Buchem

CTMM Program Manager
Henny Bruinewoud

Sponsors & Partners

BAC

Cyclotron

Leids Universitair Centrum

Maastricht University Medical Center

Merck-Sharpe & Dome

Philips Electronics

To-BBB

Universitair Medisch Centrum St. Radbod

Virtual Proteins

VU Medisch Centrum

Last Updated: 04/15/2016
The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.
Register your consortium  
All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.